Showing results (141-150 of 409) with videos related to

Sort By:
Pageof 41
Molecular Therapy. Oncology|July 18, 2024
DARPin-fused T cell engager for adenovirus-mediated cancer therapyPatrick C Freitag, Jonas Kolibius, Ronja Wieboldt, et al.
Molecular Therapy. Oncology|July 24, 2024
Electrophilic proximity-inducing synthetic adapters enhance universal T cell function by covalently enforcing immune receptor signalingNickolas J Serniuck, Eden Kapcan, Duane Moogk, et al.
Molecular Therapy. Oncology|June 24, 2024
Deletion of CD38 enhances CD19 chimeric antigen receptor T cell functionKimberly Veliz, Feng Shen, Olga Shestova, et al.
Molecular Therapy. Oncology|July 5, 2024
Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphomaDavid H Quach, Haran R Ganesh, Yolanda D Briones, et al.
Molecular Therapy. Oncology|June 28, 2024
Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cellsKelly T Kennewick, Yukiko Yamaguchi, Jackson Gibson, et al.
Molecular Therapy. Oncology|July 19, 2024
A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapyYue Wu, Xiao Liang, Yanping Sun, et al.
Molecular Therapy. Oncology|July 25, 2024
The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cellsAnnalisa Carretta, Aldo Moscardini, Giovanni Signore, et al.
Molecular Therapy. Oncology|April 10, 2024
Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cellsJong Hyeon Yoon, Han-Na Yoon, Hyun Ju Kang, et al.
Molecular Therapy. Oncology|April 10, 2024
TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1Christina Funk, Nadja Uhlig, Zsolt Ruzsics, et al.
Molecular Therapy. Oncology|April 10, 2024
Conditionally replicative adenovirus as a therapy for malignant peripheral nerve sheath tumorsJulia A Nikrad, Robert T Galvin, Mackenzie M Sheehy, et al.
Pageof 41